The story of the erectile dysfunction drug presents a complex picture for shareholders. While the initial release generated significant gains, the expiration of its exclusive rights opened the floodgates to generic https://gerardesve503794.kylieblog.com/42346623/sildenafil-and-big-pharma-a-volatile-investment